Positive Controls in Western Blotting: Selection and Validation

A positive control in western blotting is a sample known to contain the target protein of interest, used to confirm that the detection system (antibodies, reagents, and equipment) is functioning correctly and that the observed signal genuinely represents the target protein rather than non-specific binding or experimental artifact. Positive controls are essential for validating antibody specificity, establishing optimal detection conditions, and providing a reference for relative quantification. They are most useful when establishing a new assay, testing a new antibody lot, troubleshooting failed blots, or comparing protein expression levels across experimental samples. Without a properly selected and validated positive control, a negative result cannot be confidently interpreted as absence of the target protein—it may simply reflect a failed detection system.

At a Glance

Scientific Principle

Western blotting relies on the specific interaction between an antibody and its target protein, which has been separated by molecular weight via SDS-PAGE and transferred to a membrane. A positive control serves as the gold standard for demonstrating that this interaction is specific and detectable under the experimental conditions used. The principle is straightforward: if the antibody detects a band at the correct molecular weight in a sample known to contain the protein, the detection system is validated. If no band appears, the failure can be attributed to the control sample, the antibody, or the detection reagents, rather than to the experimental samples.

The scientific rationale for positive controls extends beyond simple validation. They enable relative quantification by providing a reference point for comparing signal intensity across different blots or experiments. They also help distinguish between specific and non-specific binding—a band that appears at the same molecular weight in both positive control and experimental samples is more likely to be specific than a band that appears only in experimental samples at an unexpected size. In studies examining protein expression changes, such as those investigating the ANGPT1-GABARAP axis in Crohn's disease [1], positive controls from known expressing tissues or cell lines provide the baseline for interpreting experimental results.

Materials and Instrumentation Choices

Positive Control Sample Types

The choice of positive control depends on the target protein's expression pattern and the availability of validated reagents.

Recombinant protein controls are purified proteins expressed in bacterial, insect, or mammalian systems. They offer the advantage of known concentration and purity, allowing precise loading and quantification. However, they may lack post-translational modifications present in native proteins, potentially affecting antibody recognition. Recombinant proteins are ideal for confirming antibody binding but may not reflect the full-length protein's behavior in complex lysates.

Cell lysate controls from cell lines known to express the target protein are the most biologically relevant positive controls. These can be from:

• Overexpressing cell lines: Cells transfected with a plasmid encoding the target protein, producing high levels for easy detection. This approach was used in studies of the SMAC-mimetic xevinapant, where HPV-positive HNSCC cell lines served as positive controls for cIAP1 degradation [2].
• Endogenously expressing cell lines: Cells that naturally express the target at detectable levels. For example, in studies of intrathecal IgA elevation in multiple sclerosis, CSF samples from MS patients served as positive controls for IgA detection [3].
• Tissue lysates: Homogenized tissue samples from organs known to express the target. In neurofibromatosis research, normal nerve tissue served as a control for comparing EPB41L3 expression [4].

Loading controls (e.g., β-actin, GAPDH, tubulin) are a specialized type of positive control used to verify equal protein loading across lanes. They are not substitutes for target-specific positive controls but are essential for normalization.

Antibody Considerations

The primary antibody must be validated for the species and sample type being tested. Key considerations include:

• Species reactivity: Ensure the antibody recognizes the target in the species of your experimental samples (human, mouse, rat, etc.)
• Clonality: Monoclonal antibodies offer higher specificity but may recognize only one epitope; polyclonal antibodies may detect multiple isoforms or modified forms
• Validation status: Use antibodies that have been validated by the manufacturer or in published literature with appropriate positive controls

Detection System

The choice of detection method (chemiluminescence, fluorescence, or colorimetric) affects sensitivity and dynamic range. Chemiluminescence is most common for routine use, while fluorescence enables multiplex detection. The detection system must be compatible with the secondary antibody and imaging equipment.

Controls

Essential Positive Controls

Target-specific positive control: A sample containing the protein of interest at a detectable concentration. This can be:

• Recombinant protein (0.1-10 ng per lane, depending on antibody sensitivity)
• Cell lysate from a known expressing cell line (10-50 µg total protein per lane)
• Tissue lysate from a known expressing tissue (10-50 µg total protein per lane)

Loading control: A constitutively expressed protein (e.g., β-actin, GAPDH) detected on the same membrane to verify equal protein loading and transfer efficiency.

Molecular weight markers: Pre-stained protein ladders that allow size estimation of detected bands.

Additional Validation Controls

Negative control: A sample known to lack the target protein, such as:

• Knockout cell lysate (cells with the target gene deleted)
• Tissue from a knockout animal
• Cell lysate treated with siRNA or CRISPR to reduce target expression

Blocking peptide control: Pre-incubating the primary antibody with the immunizing peptide should eliminate or reduce the specific signal, confirming antibody specificity.

Secondary antibody-only control: Omitting the primary antibody to detect non-specific binding of the secondary antibody.

Isotype control: Using a non-specific antibody of the same isotype as the primary antibody to control for non-specific binding.

Control Placement on the Gel

Positive controls should be loaded in a lane adjacent to experimental samples for direct comparison. Include at least one positive control lane per blot, and consider duplicate lanes for reproducibility. For quantification, load a dilution series of the positive control to generate a standard curve.

Conceptual Workflow

Step 1: Select the Positive Control

Identify a reliable source of the target protein. For a novel target, start with:

1. Search published literature for cell lines or tissues known to express the protein
2. Consult protein expression databases (e.g., The Human Protein Atlas)
3. Consider purchasing validated recombinant protein from commercial sources
4. If necessary, generate an overexpressing cell line using transient transfection

Step 2: Prepare the Control Sample

For cell lysates:

1. Culture cells to 70-80% confluence
2. Wash with ice-cold PBS
3. Lyse in appropriate buffer (RIPA, SDS, or urea-based) containing protease and phosphatase inhibitors
4. Centrifuge at 12,000-16,000 × g for 10-15 minutes at 4°C
5. Collect supernatant and quantify protein concentration using BCA or Bradford assay
6. Aliquot and store at -80°C

For recombinant proteins:

1. Reconstitute according to manufacturer's instructions
2. Dilute in loading buffer to appropriate concentration
3. Store aliquots at -80°C

Step 3: Run the Gel and Transfer

1. Load equal amounts of total protein (typically 10-50 µg for cell lysates, 0.1-10 ng for recombinant proteins)
2. Include molecular weight markers in at least one lane
3. Run SDS-PAGE at appropriate voltage (100-150 V) until dye front reaches the bottom
4. Transfer to PVDF or nitrocellulose membrane using wet or semi-dry transfer

Step 4: Block and Probe

1. Block membrane in 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature
2. Incubate with primary antibody at optimized dilution (typically 1:500-1:5000) overnight at 4°C
3. Wash 3×10 minutes with TBST
4. Incubate with HRP- or fluorophore-conjugated secondary antibody (1:2000-1:10000) for 1 hour at room temperature
5. Wash 3×10 minutes with TBST

Step 5: Detect and Analyze

1. Apply chemiluminescent substrate or scan for fluorescence
2. Image using appropriate detection system
3. Analyze band intensity using image analysis software
4. Normalize to loading control for relative quantification

Quality Checks

Pre-Experiment Quality Checks

• Antibody validation: Confirm the antibody has been validated for western blotting in the species of interest
• Control sample verification: Verify the positive control sample has detectable protein concentration and is not degraded
• Reagent freshness: Check expiration dates of antibodies, detection reagents, and buffers
• Equipment calibration: Ensure the power supply, transfer apparatus, and imager are functioning correctly

During-Experiment Quality Checks

• Protein loading verification: Use Ponceau S staining after transfer to confirm equal loading and transfer efficiency
• Molecular weight marker visibility: Ensure markers are clearly visible on the membrane
• Positive control signal: The positive control should produce a strong, clean band at the expected molecular weight
• Loading control signal: The loading control should show consistent intensity across all lanes

Post-Experiment Quality Checks

• Band specificity: The positive control band should be at the expected molecular weight with minimal background
• Signal linearity: For quantification, ensure the signal is within the linear range of the detection system
• Reproducibility: Repeat the experiment at least twice to confirm results
• Negative control verification: If using a knockout or knockdown control, confirm absence of signal

Result Interpretation

Expected Results

A successful western blot with a positive control should show:

• A clear, specific band at the expected molecular weight in the positive control lane
• Minimal non-specific binding (background)
• Consistent loading control signal across all lanes
• Experimental samples showing bands at the same molecular weight as the positive control (if the target is present)

Interpreting Positive Control Results

Strong signal in positive control: Confirms antibody specificity and detection system function. Experimental samples can be compared to this reference.

Weak or absent signal in positive control: Indicates a problem with the control sample, antibody, or detection system. Troubleshoot before interpreting experimental samples.

Multiple bands in positive control: May indicate degradation products, post-translational modifications, splice variants, or non-specific binding. Compare to published literature and consider using a blocking peptide or knockout control.

Signal at unexpected molecular weight: Could indicate non-specific binding, cross-reactivity, or a modified form of the protein. Validate with additional controls.

Normalization and Quantification

For relative quantification, normalize target protein signal to the loading control signal:

1. Measure integrated density of target band and loading control band
2. Calculate ratio: target signal / loading control signal
3. Compare ratios across experimental conditions

The positive control provides a reference for inter-blot comparisons. Include the same positive control on every blot to normalize for day-to-day variations in detection efficiency.

Troubleshooting

Limitations

Positive controls in western blotting have several important limitations that researchers must recognize:

Semi-quantitative nature: Western blotting is at best semi-quantitative. The relationship between protein amount and signal intensity is not linear across a wide range. For accurate quantification, use a dilution series of the positive control to establish the linear range.

Antibody-dependent specificity: The positive control only validates the antibody's ability to detect the target under the specific conditions used. Different antibodies may recognize different epitopes or isoforms, and results may not transfer between antibodies.

Sample matrix effects: A recombinant protein positive control may behave differently in buffer than the same protein in a complex cell lysate. Matrix components can affect protein stability, antibody binding, and detection efficiency.

Post-translational modifications: Recombinant proteins expressed in bacterial systems may lack mammalian post-translational modifications (glycosylation, phosphorylation, ubiquitination), potentially affecting antibody recognition. Use mammalian-expressed recombinant proteins or cell lysate controls when modifications are important.

Isoform specificity: Many proteins exist as multiple isoforms due to alternative splicing. A positive control expressing one isoform may not validate detection of another isoform. Verify which isoforms your antibody recognizes.

Dynamic range limitations: Chemiluminescent detection has a limited dynamic range (typically 2-3 orders of magnitude). Very high or very low expression levels may fall outside this range, requiring sample dilution or concentration.

No absolute quantification: Without purified protein standards of known concentration, western blotting provides only relative quantification. For absolute quantification, use recombinant protein standards or alternative methods like ELISA or mass spectrometry.

Documentation

Proper documentation of positive controls is essential for reproducibility and data integrity. Maintain a laboratory notebook or electronic record containing:

Control Sample Information

• Source of control (cell line, tissue, recombinant protein)
• Catalog number and lot number (for commercial reagents)
• Passage number (for cell lines)
• Preparation date and storage conditions
• Protein concentration and quantification method
• Number of freeze-thaw cycles

Antibody Information

• Antibody name, catalog number, and lot number
• Host species and clonality
• Recommended dilution and incubation conditions
• Validation status and references
• Date received and expiration date

Experimental Details

• Gel percentage and buffer composition
• Transfer method and conditions
• Blocking agent and conditions
• Primary and secondary antibody dilutions and incubation times
• Detection method and exposure time
• Imaging system and settings

Results Documentation

• Raw images (unprocessed) with molecular weight markers visible
• Processed images with annotations
• Quantification data and normalization calculations
• Positive control signal intensity and consistency across experiments

Biosafety Considerations

The positive controls described in this article fall within BSL-1 routine laboratory practice as defined by the CDC and NIH [6]. Key biosafety considerations include:

Cell lysate preparation: When working with human cell lines, treat all biological materials as potentially infectious. Use BSL-2 practices for cell lines that are not well-characterized or that may contain latent viruses. Follow institutional biosafety committee guidelines for recombinant DNA work, including the generation of overexpressing cell lines [7].

Recombinant proteins: Recombinant protein expression and purification may require institutional approval under the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules [7]. Ensure proper containment and decontamination procedures are in place.

Chemical hazards: SDS-PAGE and western blotting involve hazardous chemicals including acrylamide (neurotoxin), TEMED, ammonium persulfate, and methanol. Use appropriate personal protective equipment (gloves, lab coat, safety glasses) and work in a fume hood when handling these reagents.

Waste disposal: Dispose of acrylamide gels, membranes, and contaminated buffers according to institutional hazardous waste guidelines. Chemiluminescent substrates and developing solutions may contain compounds requiring special disposal.

General laboratory safety: Follow standard microbiological practices including hand washing, no eating or drinking in the laboratory, and proper labeling of all reagents and samples [6]. Maintain a clean and organized workspace to prevent cross-contamination.

Frequently Asked Questions

Q1: Can I use the same positive control for multiple target proteins on the same blot?

Yes, if the control sample expresses all target proteins of interest. For example, a cell lysate from a cell line known to express multiple proteins can serve as a positive control for each target when using multiplex detection or sequential stripping and reprobing. However, ensure that the expression levels are sufficient for detection of each target and that the molecular weights are distinct enough to resolve on the gel. For targets with similar molecular weights, consider using separate blots or different control samples.

Q2: How do I choose between recombinant protein and cell lysate as a positive control?

Recombinant protein controls are best for confirming antibody binding specificity and for absolute quantification, as they provide a known concentration of pure protein. Cell lysate controls are better for validating detection in a biologically relevant context, as they contain the full complement of cellular proteins and post-translational modifications. For most applications, use both: recombinant protein to confirm antibody specificity and cell lysate to validate detection in the experimental sample matrix. If only one can be used, choose cell lysate for biological relevance.

Q3: What should I do if my positive control shows multiple bands?

Multiple bands in a positive control can indicate several issues. First, check the molecular weight of the bands against known isoforms, splice variants, or post-translationally modified forms of your target protein. If the bands correspond to known variants, they may be specific. If not, perform a blocking peptide control to determine which bands are specific. Reduce antibody concentration to minimize non-specific binding. Consider using a different antibody that has been better characterized. If degradation is suspected, use fresh sample with protease inhibitors and minimize freeze-thaw cycles.

Q4: How often should I validate my positive control?

Validate your positive control whenever you change any critical reagent or condition. This includes: using a new lot of primary antibody, switching to a different detection system, changing the lysis buffer or protocol, or starting work with a new cell line or tissue type. For routine experiments with established reagents, validate the positive control at least every six months or whenever you observe unexpected results. Document all validation experiments in your laboratory notebook for traceability.

References and Further Reading

1. Li Y, He J, Gao P, et al. ANGPT1-GABARAP axis modulates NLRP3 inflammasome-mediated pyroptosis in Crohn's disease. 2026. https://pubmed.ncbi.nlm.nih.gov/42358953/

2. Tsai TY, Kawabe M, Kaga AN, et al. The SMAC-mimetic xevinapant differentially enhances cisplatin and immune checkpoint blockade efficacy in high-risk HPV-positive tumors. 2026. https://pubmed.ncbi.nlm.nih.gov/42235210/

3. Apeltsin L, Asokan S, Freitas B, et al. Multiplex Detection of Immunoglobulins Uncovers Intrathecal IgA Elevation in Multiple Sclerosis. 2026. https://pubmed.ncbi.nlm.nih.gov/42193880/

4. Tao E, Zhou L, Xu Z, et al. Loss of EPB41L3: a common molecular link in the tumorigenesis of neurofibromatosis types 1 and 2. 2026. https://pubmed.ncbi.nlm.nih.gov/42245745/

5. Liu Y, Zhang W, Liu Y, et al. Causal association and molecular mechanisms of periodontal disease and muscle wasting and atrophy: Mendelian randomization and bioinformatics analysis. 2026. https://pubmed.ncbi.nlm.nih.gov/42245403/

6. CDC and NIH. Biosafety in Microbiological and Biomedical Laboratories (BMBL), 6th Edition. U.S. Department of Health and Human Services, 2020. https://www.cdc.gov/labs/bmbl/index.html

7. National Institutes of Health. NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. https://osp.od.nih.gov/policies/biosafety-and-biosecurity-policy/nih-guidelines-for-research-involving-recombinant-or-synthetic-nucleic-acid-molecules/

8. National Center for Biotechnology Information. NCBI Bookshelf: Molecular Biology and Laboratory Methods. https://www.ncbi.nlm.nih.gov/books/

Related Articles

• How to Set Up and Interpret Positive Controls in Gram Staining
• Positive Control Selection for Bacterial Transformation Efficiency Assays
• Positive and Negative Controls in Antibiotic Susceptibility Testing (Kirby-Bauer)
• How to Use a Hemocytometer for Yeast Cell Counting: Protocol and Controls
• Negative Staining in Electron Microscopy: Principles and Controls
• Process Controls in Spectrophotometry: Blanking and Wavelength Verification